Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARIEL-ENGIC04 UK biomarker-guided anti-EGFR trial in right-sided advanced colorectal cancer
ISRCTN11061442Phase 4Recruiting
- Sponsor
- University of Leeds
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, open-label trial of cetuximab and panitumumab in colorectal cancer (CRC) and colon adenocarcinoma, sponsored by University of Leeds. Started Apr 2022; status: recruiting.
02
Drugs
cetuximabpanitumumab
03
Conditions
colorectal cancer (CRC)colon adenocarcinoma
Beyond the preview
Go deeper on ISRCTN11061442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11061442.